Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension ("PAH"), today announced the appointment of veteran biopharma executive Timothy Pigot as the Company's Chief Commercial and Strategy Officer.

"Tim Pigot is an accomplished pharma industry business leader and a deeply respected expert in the PAH market landscape, and we are delighted to welcome him to the Inhibikase team," said Mark Iwicki, Chief Executive Officer of Inhibikase. "As we advance IKT-001 toward a late-stage clinical trial in PAH, Tim's insights into the PAH therapeutic landscape and connections with key thought leaders will be invaluable. We look forward to his guidance and contributions."

Mr. Pigot is an accomplished pharmaceutical industry executive with over three decades of experience in both large pharma and start up organizations. Most recently he served as Chief Commercial Officer of Aerovate Therapeutics, where he led commercial planning and strategy for the Company's therapeutic candidate in PAH. Previously Mr. Pigot was Vice President of Marketing for MyoKardia, where he led commercial launch strategy for mavacamten, a first in class cardiac myosin inhibitor. Earlier in his career, Mr. Pigot held several leadership positions at Gilead Sciences and Pfizer, where he led sales, marketing, and operations for products in the PAH, cardiopulmonary, CNS and oncology therapeutic areas. Mr. Pigot earned his Bachelor of Sciences degree from the SUNY Binghamton School of Management.

About Inhibikase ( www.inhibikase.com )

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension ("PAH"), that arise from aberrant signaling through the Abelson Tyrosine Kinase, and type III receptor tyrosine kinases including platelet derived growth factor receptors and c-KIT. Our lead product candidate is IKT-001, a prodrug of imatinib mesylate, for PAH which is an orphan indication. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans.

Social Media Disclaimer

Investors and others should note that the Company announces material financial information to investors using its investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use LinkedIn and YouTube as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as "believes," "expects," "may," "will," "should," "anticipates," "plans," or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements that express the Company's intentions, beliefs, expectations, strategies, predictions or any other statements related to the initiation of the Company's Phase 2b trial of IKT-001 in PAH and the Company's future activities, or future events or conditions; and expectations regarding the anticipated contribution of our new leadership team to our operations and progress. These forward-looking statements are based on Inhibikase's current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase's actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include our ability to commence and execute a Phase 2b ‘702' trial to evaluate IKT-001 as a treatment for PAH, as well as such other factors that are included in our periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

Contacts:
Investor Relations:
Michael Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

IKT
The Conversation (0)
Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its lead program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. The company is performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. It is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease.

Altech Batteries Ltd  CERENERGY Battery Prototype Reaches Key Milestones

Altech Batteries Ltd CERENERGY Battery Prototype Reaches Key Milestones

Perth, Australia (ABN Newswire) - Altech Batteries Limited (ASX:ATC,OTC:ALTHF) (FRA:A3Y) (OTCMKTS:ALTHF) is pleased to announce the latest performance results of the CERENERGY(R) cell and battery pack prototypes. These results confirm the technological maturity and robustness of the CERENERGY(R) technology and mark another decisive step towards industrialisation.

Highlights

- 650+ cycles with no capacity loss, proving exceptional material stability and long operational lifespan compared to conventional batteries

- Near 100% Coulombic efficiency, confirming minimal side reactions and strong intrinsic safety of sodium nickel chloride chemistry

- High energy efficiency of up to 92%, surpassing typical 70-80% levels of competing battery technologies

- Proven safety under extreme conditions - cells remained stable during overcharge, deep discharge, and thermal cycling up to 300 degC with no gassing, leakage, or rupture

- Robust and reliable chemistry - sodium nickel chloride avoids flammable electrolytes and runaway risks, confirming suitability for safe, large-scale grid and renewable energy storage

- ABS60 prototype validated under real-world conditions -tested across diverse load profiles, high-current pulses up to 50 A, and thermal variations

- Stable, efficient performance - achieved ~88% round-trip efficiency with no observable capacity fade over 110+ cycles

CELL PERFORMANCE

The CERENERGY(R) prototype cells have successfully completed over 650 charge-discharge cycles without any detectable capacity loss. Cycle life is a critical measure of battery durability, as most conventional batteries experience gradual degradation with every cycle. Achieving such performance highlights the outstanding stability of the materials and points to the potential for a long operational lifespan.

For stationary energy storage systems (ESS), this translates into fewer battery replacements, lower lifetime operating costs, and greater reliability for end users.

The cells also delivered nearly 100% Coulombic efficiency alongside an energy efficiency of up to 92% across 650 cycles. Coulombic efficiency reflects the proportion of charge recovered during discharge relative to what was supplied during charging. A value approaching 100% indicates minimal side reactions or parasitic losses, confirming the intrinsic stability and safety of sodium nickel chloride chemistry. This high efficiency demonstrates that the cells are not expending energy on unwanted processes such as electrode degradation. Such performance is vital for scalability, ensuring reliable, longterm operation in commercial energy storage applications.

Energy efficiency represents the proportion of energy delivered relative to the energy supplied. Competing technologies, including conventional high-temperature batteries and many flow batteries, typically achieve only around 70-80%. By reaching 92%, CERENERGY(R) positions itself in a highly competitive class, offering more cost-effective energy storage, stronger economics for grid operators, and seamless compatibility with the requirements of renewable energy integration.

The cells achieved a nominal capacity of 100 Ah and 250 Wh, with reliable performance even at higher discharge rates. A key feature is their ability to support multiple daily charge-discharge cycles within the 20-80% state of charge (SoC) range at 25 A. This capability positions CERENERGY(R) as a highly flexible solution for grid operators and energy storage providers, enabling cost-efficient, long-life performance in applications that demand frequent cycling such as renewable integration, peak shaving, and backup power.

CERENERGY(R) prototype cells underwent rigorous abuse testing, including overcharge to 4 V, deep discharge to 0.2 V, and thermal cycling between room temperature and 300 degC. In all cases, the cells remained stable with no gassing, leakage, or rupture -clear proof of their outstanding safety. These results highlight the intrinsic stability of sodium nickel chloride chemistry, which avoids the flammable electrolytes and runaway risks common in lithium-ion batteries. The ability to withstand extreme electrical and thermal stress demonstrates CERENERGY(R)'s robustness and confirms its suitability for safe, largescale deployment in grid, renewable, and industrial energy storage applications. This was achieved over 3 cycles with 1.8 Full Charge Equivalent (FCE) into 22 hours.

BATTERY PACK ABS60 (60 kWh) PROTOTYPE

The first ABS60 battery pack prototype has been successfully validated under real-world operating conditions, marking a major step forward in product readiness. Testing included diverse load profiles,

continuous discharges at 25 A (equivalent to C-rate of C/4 (discharges in 4 hours), or one-quarter of the pack's rated capacity per hour) at 80% depth of discharge (DoD), short-duration high-current pulses up to 50 A, and carefully controlled thermal variations.

The pack consistently demonstrated stable performance, achieving ~88% round-trip efficiency while maintaining reliable thermal management. Efficiency refers to the proportion of input energy that can be retrieved during operation-a critical measure of economic viability for large-scale storage. Over more than 110 cycles, results showed no observable capacity fading and only a slight increase in internal resistance. Capacity fading refers to the gradual decline in usable energy over repeated cycles, while internal resistance influences power delivery and heat generation.

The absence of meaningful degradation confirms the durability and electrochemical stability of the ABS60 design. These outcomes are highly significant as they demonstrate that the pack can withstand real-world duty cycles while retaining performance and efficiency, translating into longer service life, fewer replacements, and lower total cost of ownership.

For grid operators and renewable integration projects, this combination of robust cycling capability, efficiency, and thermal stability underscores the ABS60's commercial readiness and competitive advantage in the stationary energy storage market.

These results are a strong confirmation of CERENERGY(R)'s technological leadership and a clear signal of the technology's competitiveness and robustness for future applications in energy storage and industrial markets.

Group Managing Director, Iggy Tan said "These results confirm CERENERGY(R)'s robustness and readiness for market adoption. Demonstrating long cycle life, high efficiency, and unmatched safety, we are now strongly positioned to deliver a competitive and sustainable alternative for grid and industrial energy storage."

*To view photographs, tables and figures, please visit:
https://abnnewswire.net/lnk/17QS44T3



About Altech Batteries Ltd:

Altech Batteries Limited (ASX:ATC,OTC:ALTHF) (FRA:A3Y) is a specialty battery technology company that has a joint venture agreement with world leading German battery institute Fraunhofer IKTS ("Fraunhofer") to commercialise the revolutionary CERENERGY(R) Sodium Alumina Solid State (SAS) Battery. CERENERGY(R) batteries are the game-changing alternative to lithium-ion batteries. CERENERGY(R) batteries are fire and explosion-proof; have a life span of more than 15 years and operate in extreme cold and desert climates. The battery technology uses table salt and is lithium-free; cobalt-free; graphite-free; and copper-free, eliminating exposure to critical metal price rises and supply chain concerns.

The joint venture is commercialising its CERENERGY(R) battery, with plans to construct a 100MWh production facility on Altech's land in Saxony, Germany. The facility intends to produce CERENERGY(R) battery modules to provide grid storage solutions to the market.

News Provided by ABN Newswire via QuoteMedia

Keep reading...Show less
Altech Batteries Ltd  Bearer Bond Funds Received

Altech Batteries Ltd Bearer Bond Funds Received

Perth, Australia (ABN Newswire) - Altech Batteries Limited (ASX:ATC,OTC:ALTHF) (FRA:A3Y) (OTCMKTS:ALTHF) is pleased to announce that it has received EUR1M in funds from the remaining Bearer Bond facility in place with major shareholder Deutsche Balaton. The original facility was for EUR2.5M and this has now been adjusted by mutual agreement to EUR2M. The full EUR2M has now been drawn down.

As announced to the ASX on 25 March 2025, the Company advised that it is in the process of selling its Malaysian land to help fund the ongoing development of the CERENERGY(R) battery project and the Silumina Anodes(TM) battery materials project, as well as to support general working capital requirements.

The Company also announced that it had entered into a binding Bond Note Subscription Deed with its major shareholder Deutsche Balaton AG, under which Altech could drawdown up to EUR2.5M in cash in the form of interest-bearing Bearer Bonds.

As the Bond Note Subscription Deed involved the Company granting a security interest over the Company's Malaysian land, shareholder approval was required. The Company convened a General Meeting on 13 May 2025 and shareholders approved all Resolutions put to the General Meeting. The Company then applied to have the Malaysian land security registered with the relevant land authority, being Johor Corp. Although there were no laws or regulations precluding Johor Corp from registering the land security, it considered Deutsche Balaton AG a 'non-lending foreign entity' and advised that accordingly it was not comfortable in registering the land security.

The Company's wholly owned subsidiary Altech Chemicals Sdn. Bhd. is the holder of the lease agreement over the Malaysian land. The only asset of value within Altech Chemicals Sdn. Bhd. is the lease agreement over the Malaysian land. In order to provide the security to Deutsche Balaton AG so as to drawdown the Bearer Bonds, the Company enforced security over the shares of Altech Chemicals Sdn. Bhd. in favour of Deutsche Balaton AG in lieu of the land security.

On 20 August 2025, the Company's wholly owned subsidiary Altech Chemicals Australia Pty Ltd (shareholder of Altech Chemicals Sdn. Bhd.) executed a Share Charge with Deutsche Balaton AG in connection with the Bond Note Subscription Deed. Pursuant to the Share Charge, Altech Chemicals Australia Pty Ltd has offered as a continuing Security for the due and punctual payment of all the requirements of the Bond Note Subscription Deed, charged all its rights, title and interest to all of the shares held in Altech Chemicals Sdn. Bhd. in favour of Deutsche Balaton AG. The Security is a continuing security and will extend to the ultimate balance of the due and punctual payment of all the requirements of the Bond Note Subscription Deed.

On 20 August 2025, the Company executed an Amendment Deed to the Bond Note Subscription Deed. Under the terms of the Amendment Deed, the agreed amount of bonds available to be drawdown was reduced from EUR2.5M to EUR2.0M. Additionally, the Company's Meckering land was offered as additional security for the due and punctual payment of all the requirements of the Bond Note Subscription Deed.

Altech Meckering Pty Ltd, the Company's wholly owned subsidiary and holder of the Meckering land, has entered into a mortgage over the Meckering Land in favour of Deutsche Balaton AG as a continuing Security for the due and punctual payment of all the requirements of the Bond Note Subscription Deed.



About Altech Batteries Ltd:

Altech Batteries Limited (ASX:ATC,OTC:ALTHF) (FRA:A3Y) is a specialty battery technology company that has a joint venture agreement with world leading German battery institute Fraunhofer IKTS ("Fraunhofer") to commercialise the revolutionary CERENERGY(R) Sodium Alumina Solid State (SAS) Battery. CERENERGY(R) batteries are the game-changing alternative to lithium-ion batteries. CERENERGY(R) batteries are fire and explosion-proof; have a life span of more than 15 years and operate in extreme cold and desert climates. The battery technology uses table salt and is lithium-free; cobalt-free; graphite-free; and copper-free, eliminating exposure to critical metal price rises and supply chain concerns.

The joint venture is commercialising its CERENERGY(R) battery, with plans to construct a 100MWh production facility on Altech's land in Saxony, Germany. The facility intends to produce CERENERGY(R) battery modules to provide grid storage solutions to the market.

News Provided by ABN Newswire via QuoteMedia

Keep reading...Show less
Altech Batteries Ltd  CERENERGY Battery 46.7M Euro German Grant Approval

Altech Batteries Ltd CERENERGY Battery 46.7M Euro German Grant Approval

Perth, Australia (ABN Newswire) - Altech Batteries Limited (ASX:ATC,OTC:ALTHF) (FRA:A3Y) (OTCMKTS:ALTHF) is pleased to announce that it has received official written confirmation for the grant qualification of the CERENERGY(R) sodium-chloride solid-state battery project in Saxony, Germany to the value of 30% of the total capital expenditure excluding working capital, financing cost and interest during construction amounting to EUR46,725,802.

Highlights

- Altech Batteries GmbH's CERENERGY(R) battery project has been approved by Germany's Ministry of Economic Affairs and Energy as eligible for Grant receipt under the "STARK"(1) economic development program

- Altech Batteries GmbH's CERENERGY(R) battery project passed the second stage of Government approval for a 30% CAPEX grant in the amount of 46.7 million Euro

- The grant approval is not yet final and conditional and subject to overall financial close and the availability of funds to be approved by the German parliament as part of the 2026 Government Budget

(1) STARK - Starkung der Transformationsdynamik und Aufbruch in den Revieren und an den Kohlekraftwerkstandorten

The STARK program supports projects that support the transformation process towards an ecologically, economically, and socially sustainable economic structure in the coal regions and is initiated by the German Federal Government and supported by the EU

Altech has been actively applying for various grants offered by the State of Saxony, Federal Government of Germany, and the European Union. The State of Saxony and Brandenburg, along with the European Union, offer substantial support for renewable energy projects, including grants under the STARK program aimed at converting lignite coal to renewable energy sources. These grants are part of broader efforts to transition regions dependent on fossil fuels toward sustainable energy solutions. Altech's site, located in these areas, stands to benefit from various funding programs designed to support clean energy projects, including EU grants for energy transformation and innovation.

Having now received written confirmation of the STARK program for the CERENERGY(R) project, it is a great sign of support and a recognition of this innovative battery technology jointly undertaken by Altech and the Fraunhofer Gesellschaft.



About Altech Batteries Ltd:

Altech Batteries Limited (ASX:ATC,OTC:ALTHF) (FRA:A3Y) is a specialty battery technology company that has a joint venture agreement with world leading German battery institute Fraunhofer IKTS ("Fraunhofer") to commercialise the revolutionary CERENERGY(R) Sodium Alumina Solid State (SAS) Battery. CERENERGY(R) batteries are the game-changing alternative to lithium-ion batteries. CERENERGY(R) batteries are fire and explosion-proof; have a life span of more than 15 years and operate in extreme cold and desert climates. The battery technology uses table salt and is lithium-free; cobalt-free; graphite-free; and copper-free, eliminating exposure to critical metal price rises and supply chain concerns.

The joint venture is commercialising its CERENERGY(R) battery, with plans to construct a 100MWh production facility on Altech's land in Saxony, Germany. The facility intends to produce CERENERGY(R) battery modules to provide grid storage solutions to the market.

News Provided by ABN Newswire via QuoteMedia

Keep reading...Show less
Altech Batteries Ltd  Cerenergy Battery Project Funding Progressing Well

Altech Batteries Ltd Cerenergy Battery Project Funding Progressing Well

Perth, Australia (ABN Newswire) - Altech Batteries Limited (ASX:ATC,OTC:ALTHF) (FRA:A3Y) (OTCMKTS:ALTHF) is pleased to announce an update on funding of the CERENERGY(R) sodium-chloride solid-state battery project in Saxony, Germany.

DEBT PROCESS

As previously mentioned, Altech has engaged ten commercial banks and two venture debt funds in the first round of financing discussions, receiving largely positive initial feedback. Based on this feedback, the Company has selected a preferred financial institution- a European bank with a proven track record in providing debt funding for technology-driven projects, particularly those within the innovation sector.

Although the mandate has not yet been formally executed, Altech intends to make an official announcement once this step is complete.

Meanwhile, the bank's commercial and technical teams have been diligently conducting a comprehensive review of the Cerenergy projects and its technology. The technical due diligence process is critical for ensuring that the project meets the bank's financing and risk criteria. As part of this process the onsite Altech experts are in detailed discussions with the bank's representative. The banks have visited Dresden and the Fraunhofer testing facilities and visit Hermsdorf, Germany where the prototype production is located in the coming weeks, which will be a key step in concluding the technical evaluation.

In parallel with these efforts, Altech is progressing discussions for securing a federal government guarantee, which would further strengthen its ability to secure the necessary debt funding for the project. Officials from the Ministry of Finance have already been briefed on the initiative, and the due diligence process for the application is actively underway. This federal guarantee will serve as an underwriter and therewith derisk any debt funding for the project substantially.

EQUITY FUNDING

In parallel with ongoing debt financing efforts, the Group has engaged several equity advisers to assist in securing the equity component of the project's funding package. As part of this strategy, Altech plans to divest a minority interest in the project to one or two strategic investors. This partial divestment is intended to attract investors who can contribute not only capital, but also strategic value, aligning with the CERENERGY(R) project's long-term goals of growth and sustainability.

The Group on one hand is specifically targeting large utility companies, data centre operators, investment funds, and corporations that are deeply committed to the green energy transition and on the other hand industrial partners with access and know-how and resources relevant to Cerenergy battery production, implementation or market access. These potential partners are seen as ideal due to their strong alignment with the project's sustainable energy focus and their ability to provide significant financial support. Progress in equity discussions has been promising, with several Non-Disclosure Agreements (NDAs) signed, enabling deeper engagement with prospective investors. Additionally, draft term sheets have been circulated to interested parties, outlining the key terms and conditions for investment. These documents provide a foundation for negotiations and facilitate more detailed discussions around the equity stake and partnership structure.

The decision to divest part of the project is strategically aimed at easing the Company's financial burden while bringing in experienced partners who can contribute to the project's success. By securing both equity and debt financing, Altech aims to finalize the full funding package, ensuring the timely construction and commissioning of the CERENERGY(R) battery plant. Moving forward, the focus will be on advancing these discussions and converting interest into formal commitments, which are critical for the project's progression.

GRANT APPLICATIONS

Altech has been actively applying for various grants offered by the State of Saxony, Federal Government of Germany, and the European Union. The State of Saxony and Brandenburg, along with the European Union, offer substantial support for renewable energy projects, including grants aimed at converting lignite coal to renewable energy sources. These grants are part of broader efforts to transition regions dependent on fossil fuels toward sustainable energy solutions. Altech's site, located in these areas, stands to benefit from various funding programs designed to support clean energy projects, including EU grants for energy transformation and innovation. Altech has applied for several of these grants to advance its CERENERGY(R) project, securing essential financial backing for technology development, high-tech industries, expert employment and infrastructure upgrades.

OFFTAKE ARRANGEMENTS

Altech has secured three key Offtake Letters of Intent (LOIs) for 100% of its CERENERGY(R) production.

1. Zweckverband Industriepark Schwarze Pumpe (ZISP): An agreement was signed on 13 September 2024 for ZISP to purchase 30 MWh of energy storage capacity annually, consisting of 1MWh GridPacks, for the first five years of production. The purchase is contingent on performance tests and battery specifications meeting customer requirements.

2. Referenzkraftwerk Lausitz GmbH (RefLau): A second LOI was executed with RefLau, a joint venture between Enertrag SE and Energiequelle GmbH. RefLau will buy 30 MWh of CERENERGY(R) storage n the first year, increasing to 32 MWh annually for the next four years. Additionally, Altech will purchase green electricity for its planned production plant.

3. Axsol GmbH: A third LOI was signed with Axsol, a leading renewable energy solutions provider. Axsol will exclusively distribute CERENERGY(R) batteries to the Western defense industry, facilitating early market entry and sales. These agreements are crucial for financing and advancing the CERENERGY(R) project.



About Altech Batteries Ltd:

Altech Batteries Limited (ASX:ATC,OTC:ALTHF) (FRA:A3Y) is a specialty battery technology company that has a joint venture agreement with world leading German battery institute Fraunhofer IKTS ("Fraunhofer") to commercialise the revolutionary CERENERGY(R) Sodium Alumina Solid State (SAS) Battery. CERENERGY(R) batteries are the game-changing alternative to lithium-ion batteries. CERENERGY(R) batteries are fire and explosion-proof; have a life span of more than 15 years and operate in extreme cold and desert climates. The battery technology uses table salt and is lithium-free; cobalt-free; graphite-free; and copper-free, eliminating exposure to critical metal price rises and supply chain concerns.

The joint venture is commercialising its CERENERGY(R) battery, with plans to construct a 100MWh production facility on Altech's land in Saxony, Germany. The facility intends to produce CERENERGY(R) battery modules to provide grid storage solutions to the market.

News Provided by ABN Newswire via QuoteMedia

Keep reading...Show less
Altech Batteries Ltd  DNV Comparison Study on CERENERGY Technology

Altech Batteries Ltd DNV Comparison Study on CERENERGY Technology

Perth, Australia (ABN Newswire) - Altech Batteries Limited (ASX:ATC) (FRA:A3Y) (OTCMKTS:ALTHF) is pleased to announce that as part of its funding strategy and due diligence plan, an independent study has been conducted on the CERENERGY(R) technology versus alternative technologies such as lithium-ion, sodium-sulphur and vanadium flow batteries. DNV was engaged to produce an independent, high-level comparison report evaluating CERENERGY(R) technology against these alternative technologies. DNV is one of the leading energy storage technical advisors and specialises in the identification, evaluation, testing, and certification of battery energy storage systems worldwide.

Highlights

- As part of funding due diligence plan

- Independent comparison study of CERENERGY(R) technology

- DNV was engaged by Altech

- DNV is one of the leading energy storage technical advisors

- CERENERGY(R) - Promising emerging battery technology

The complete comparison report has been prepared specifically for Altech Batteries GmbH and is confidential. Nevertheless, Altech is pleased to publish the Executive Summary of the technology comparison at cell level in the following qualitative overview. Table 1 gives a high-level overview of the advantages and disadvantages for the listed characteristics in comparison to the most widely used technologies on the market against CERENERGY(R) sodium chloride solid state (SCSS) technology.

The DNV primary conclusion states "CERENERGY(R) is one of the promising emerging technologies. Further improvements in terms of the achievable energy density, performance, and cost efficiency can be expected in the coming years" (DNV, May 2025).

*To view tables and figures, please visit:
https://abnnewswire.net/lnk/66D7P180



About Altech Batteries Ltd:

Altech Batteries Limited (ASX:ATC) (FRA:A3Y) is a specialty battery technology company that has a joint venture agreement with world leading German battery institute Fraunhofer IKTS ("Fraunhofer") to commercialise the revolutionary CERENERGY(R) Sodium Alumina Solid State (SAS) Battery. CERENERGY(R) batteries are the game-changing alternative to lithium-ion batteries. CERENERGY(R) batteries are fire and explosion-proof; have a life span of more than 15 years and operate in extreme cold and desert climates. The battery technology uses table salt and is lithium-free; cobalt-free; graphite-free; and copper-free, eliminating exposure to critical metal price rises and supply chain concerns.

The joint venture is commercialising its CERENERGY(R) battery, with plans to construct a 100MWh production facility on Altech's land in Saxony, Germany. The facility intends to produce CERENERGY(R) battery modules to provide grid storage solutions to the market.

News Provided by ABN Newswire via QuoteMedia

Keep reading...Show less
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and MagSense® HER2 Breast Cancer diagnostic imaging program, supporting the planned Phase 2 Clinical Trial expected to commence towards the end of 2025.

Keep reading...Show less
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare.

But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no indication that US hospitals are stockpiling equipment ahead of expected price hikes, according to recent findings from GlobalData.

Keep reading...Show less
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This establishes the timeline for the planned safety and efficacy futility interim analysis by an independent Data Monitoring Committee (DMC).

Keep reading...Show less
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic.

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less

Latest Press Releases

Related News

×